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Background: Sarcoidosis is an inflammatory multisystemic granulomatous disease of unknown
aetiology commonly affecting the lungs, and pulmonary fibrosis often develops in chronic
sarcoidosis. It has been suggested that Wnt (Wingless/integrated)-signaling has a role in
inflammatory and fibrotic processes in the lungs, but its role in sarcoidosis has not been inves-
tigated. We hypothesised that Wnts secreted from T cells or other inflammatory cells have
a role in the pathogenesis of sarcoidosis.
Methods: Brush biopsies and bronchoalveolar lavage (BAL) were obtained through bronchos-
copy from healthy controls (nZ 18) and patients with sarcoidosis (nZ 48). Semi-quantitative
RT-PCR, electrophoretic mobility shift assay (EMSA) and immunocytochemistry were per-
formed to analyse Wnt expression and activation of the Wnt-signal transducer b-catenin.
Results: Altered expression of Wnt5A, Wnt7A and Wnt7B mRNA in BAL cells was observed, as
well as an increased activation of b-catenin, measured by EMSA and confirmed with immuno-
cytochemistry, in resident lung cells from patients with sarcoidosis. More pronounced changes
in Wnt expression were seen with advancing disease stage. Thus, by three independent
methods, we have found evidence of increased pulmonary Wnt-activation in sarcoidosis.
Conclusions: In the lungs of patients with sarcoidosis there is a previously unappreciated
increased Wnt-signal activation that could contribute to the inflammatory processes.
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Sarcoidosis is a multisystemic granulomatous disease of
unknown aetiology, most commonly affecting the lungs.1
A typical accumulation of activated T helper (CD4þ) cells,
found through the use of bronchoscopy and bronchoalveolar
lavage (BAL) in patients with sarcoidosis, was described
already in the1980-ies.2 These lung-accumulatedCD4þTcells
have a Th1 cytokine profile3,4 and are considered to be of
central importance for the inflammation. The infiltrating
inflammatory cells contribute to the formation of non-case-
ating epithelioid cell granulomas. The majority of patients
recover, but somedevelopchronicdiseasewithfibrosis, and in
some cases respiratory failure. Lo¨fgren’s syndrome is a clini-
cally separate subset of sarcoidosis patients, often associated
with a good prognosis, distinguished by an acute onset of
disease, bilateral hilar lymphadenopathy, fever, erythema
nodosum and ankle arthritis or periarticular inflammation.5
Wnts are secreted glycoproteins involved in cell prolifer-
ation, differentiation andmigration. They act on cell surface
receptors to activate intracellular pathways. The dominating
canonical pathway includes the signal transducing molecule
b-catenin. When activated, b-catenin translocates to the
nucleus, where it binds to and activates TCF/Lef (T cell
factor/Leukocyte enhancing factor) transcription factors,
leading to specific gene transcription. Several of the inflam-
matory target genes6 of the Wnt/b-catenin pathway have
been shown to be up-regulated in patients with sarcoidosis.7
Based on this, we hypothesised that Wnts secreted from T
cells, or other inflammatory cells, are involved in the
inflammatory processes in sarcoidosis.We therefore used RT-
PCR to measure mRNA levels of selected Wnts in BAL cells. In
theabsenceofawell-establishedmethod todirectlymeasure
Wnt-protein levels in biological fluids, we measured activa-
tion of Wnt-signaling in biopsies by electrophoretic mobility
shift assays (EMSAs) for activated b-catenin, and by immu-
nohistochemistry for nuclear b-catenin, both well-estab-
lished and robust methods to monitor Wnt-signaling.8e10
Materials and methods
Subjects
The total number of subjects included in this study was 66.
Sarcoidosis patients (nZ 48; Table 1) were recruited when
referred to the Division of Respiratory Medicine (Karolinska
University Hospital, Stockholm, Sweden) for initial diag-
nostic investigation. Eighteen were non-smoking healthy
controls. All patients had clinical features of sarcoidosis
according to criteria established by WASOG,11 evaluated by
chest radiography, symptoms and pulmonary function tests.
None of the patients received corticosteroid treatment at
the time of the study. Detailed patient characteristics are
given in Table 1 and Table 2. The study was approved by the
local ethics committee.
Cells and samples
Brush biopsieswere obtained during fiberoptic bronchoscopy
under local anaesthesia. Three consecutive endobronchial
brushings were collected, yielding approximately 1  106cells/brush, pooled in 0.5 ml phosphate-buffered saline
(PBS) and pelleted before storage at 80 C until analysis.
BAL was performed with sterile 37 C PBS, instilled in five
50 mL aliquots in a segmental middle lobe bronchus and
immediately re-aspirated. Fluidwas collected in a siliconised
plastic bottle and stored on ice. The recovered fluid was
centrifuged at 400g for 10min at 4 C, to separate BAL cells.
The cell pellet was resuspended in RPMI1640 medium (Sig-
maeAldrich, Irvin, UK) and viability determined by trypan
blue exclusion. After Giemsa-staining, a total of 500 cells
were counted and differentiated into cell types macro-
phages, lymphocytes, eosinophils, basophils and neutro-
phils. Aliquots of 1  106 cells were pelleted and stored at
20 C until further use.
RT-PCR
RNA was extracted from total BAL cells using the RNea-
syMiniKit (Qiagen) according to the manufacturers’
instructions. RNA concentration was measured using
Nanodrop (Thermo Fisher Scientific, Wilmington, DE).
Aliquots of total RNA were converted to cDNA with Reac-
tionReady First strand cDNA synthesis kit (SABiosciences,
Frederick, MD). Primers for Wnt5A (#PPH02410A), Wnt7B
(#PPH02464A), Wnt7A (#PPH02465A) and the housekeeping
gene PSMB2 (#PPH20109A),12 as well as RT2Real-Time-
SYBRGreen PCR-Master Mix were purchased from SABio-
sciences. The reactions, with sample cDNA, primer sets and
PCR-master mix, were subjected to PCR conditions of 95 C
for 10 min, 95 C for 15 s and 60 C for 1 min, for 40 cycles in
an ABI PRISM Sequence Detector 7700 (Applied Biosystems,
Foster City, CA). PCR products were resolved by electro-
phoresis on 2% agarose gels to verify that the primer sets
amplified a product of predicted size. In addition to agarose
electrophoresis, the specificity of the PCR product was
ensured by melting curve analysis.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from brush biopsy-cells as
previously described.13 The purity of the obtained cells
were determined by differential counting of brush biopsy-
cells cytocentrifuged onto glass slides, see below. 94% of
the obtained cells were epithelial, in line with previous
publications.13 b-catenin binding activity was investigated
by EMSA using an oligonucleotide harbouring a TCF/Lef
consensus binding site (50- TGT TGT TAA GCA AAG ATC AAA
GCC CGG CAG AG- 30), end-labeled with [g32-P] ATP, as
probe. Protein concentration was measured by the Brad-
ford method14 and equal amounts was incubated with probe
before loading onto non-denaturing 5% polyacrylamide gels.
Gels were fixed and vacuum dried before visualisation of
resulting complexes by autoradiography. The intensity of
the active TCF/b-catenin shift was measured using the
freeware ImageJ.15 The images were inverted and the shift
intensity measured at the lowest point (Supplemental
Fig. 1A and B). Then, the intensity of each shift was
calculated in respect to exposure intensity of the entire
image, by subtracting the background intensity (noise) from
the total shift intensity (S) in each respective gelshift, to
account for the manual film processing. SeN intensities
were used in the statistical calculations.
Table 1 Characteristics of the study population.
qRT-PCR EMSA Immunocytochemistry
Healthy Sarcoidosis Healthy Sarcoidosis Healthy Sarcoidosis
Subjects n 8 37 5 7 5 4
Gender M/F 5/3 20/17 1/4 3/4 0/5 1/3
Age 27 (25e49) 42 (29e74) *** 22(20e35) 32 (26e46) * 24 (20e33) 34 (28e65)
Smoking NS/Ex-SM/SM 7/1/0 19/9/9 5/0/0 4/2/1 5/0/0 1/3/0
Radiographic Stage 0/I/II/III/IV 0 0/15/11/8/3 0 0/6/1/0/0 0 1/3/0/0/0
BAL Analysis
Recovery % 76.0 (67.0e94.0) 68.0 (44.0e84.0)* 74.0 (59.0e76.0) 70.5 (57.6e76.0) 79.0 (59.0e84.0) 64.0 (53.0e74.0)
Viability % 92.0 (86.0e94.0) 94.0 (82.0e98.0) 92.0 (87.0e95.0) 92.3 (82.0e98.0) 86.0 (73.0e95.0) 93.5 (80.0e97.0)
Cell Concentration x1.0Eþ06*L-1 91.3 (53.6e139.4) 153.9 (53.6e521.1)* 62.0 (42.0e99.5) 216.4 (49.1e303.2) 75.0 (62.8e88.6) 204.4 (94.0e337.0)*
Lo¨fgren’s Syndrome Yes/No e 12/21 e 0/7 e 0/4
Differential Cell Counts
Macrophages % 77.0 (62.6e92.5) 79.5 (28.0e94.8) 86.6 (75.5e94.8) 77.7 (46.6e85.8) 90.1 (67.5e94.8) 81.3 (69e85.7)
Lymphocytes % 16.3 (5.5e34.6) 18.9 (4.0e69.0) 12.4 (3e20.5) 20.2 (13.5e52.2) 6.4 (3e30.2) 16.0 (12e29.8)
Neutrophils % 1.4 (0.3e14.8) 1.2 (0.0e5.6) 2.2 (1e3.7) 0.8 (0e4.8) 2.2 (2.1e3.4) 1.725 (0.6e3.4)
Eosinophils % 0.2 (0e1.2) 0.2 (0.0e6.2) 0.0 (0e0.3) 0.0 (0e0.8) 0 (0e0.8) 0.1 (0e1.3)
Basophils % 0.0 (0e0.2) 0.0 (0.0e0.8) 0 0.0 (0e0.2) 0 0
CD4/CD8 ratio 3.45 (1.8e5.1) 4.7 (0.7e17.0) e 8.9 (4e13) e 4.7 (2.3e7.6)
Pulmonary function tests
VC% 119.0 (105.0e123.0) 90.0 (33.0e114.0)** e 94.0 (85.0e112.0) e 83.5 (82.0e85.0)
FVC% 113.5 (105.0e132.0) 91.5 (28.0e117.0)*** e 94.0 (85.0e111.0) 113.0 (104.0e116.0) 84.0 (83.0e85.0)
TLC% e 91.5 (69.0e120.0) e 93.0 (86.0e112.0) e 86.0 (86.0e86.0)
FEV1% 111.5 (91.0e119.0) 88.5 (23.0e120.0)** e 89.0 (80.0e104.0) 105.0 (100.0e107.0) 82.0 (80.0e84.0)
Data are presented as median (minimum-maximum), unless otherwise stated. EMSA: Electrophoretic mobility shift assay; VC: Vital pacity; FVC: forced vital capcity; TLC: total lung
capacity; FEV1: forced expiratory volume in 1 s; NS: Never smoker; Ex-SM: Ex-smoker; SM: Smoker; * p < 0.05; ** p < 0.01; *** p < 0.00 etween Healthy and Sarcoidosis within one study
group.
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Table 2 Characteristics of subjects in the RT-PCR experiments and BAL-findings.
Pat# Gender Age Smoking Sarcoidosis chest
radioqraphic staqe
Lofgren’s
syndrome
Macrophages % Lymphocytes % Neutrophils % Eosinophils % Basophils % vc% FVC % TLC % FEV1% CD4/CD8
HI M 27 NS 0 e 88,7 11,0 0,3 0,0 0,0 e 114 e 119 e
H2 F 32 NS 0 e 76,0 23,0 0,6 0,4 0,0 119 132 e 111 1,8
H3 M 27 NS 0 e 87,6 10,0 2,0 0,4 0,0 114 e 115 e
H4 M 25 NS 0 e 92,5 55 2,0 0,0 0,0 105 e 103 e
H5 F 26 Ex-SM 0 e 73,0 25,8 1,2 0,0 0,0 105 108 e 101 e
H6 M 25 NS 0 e 77,0 8,0 14,8 0,0 0,2 e 113 e 91 e
H7 M 27 NS 0 e 77,0 21,6 0,6 0,8 0,0 e 111 e 113 e
H8 F 49 NS 0 e 62,6 34,6 1,6 1,2 0,0 123 123 e 112 4,3
S01 F 43 NS I e 86,2 8,8 4,4 0,6 0,0 78 105 e 99 5,1
S02 M 43 NS I No 79,0 19,0 1,8 0,2 0,0 84 88 e 89 6,6
S03 F 31 NS II No 61,6 34,8 2,6 0,8 0,2 e e e e 1,0
S04 F 52 NS I Yes 88,0 10,4 1,6 0,0 0,0 80 83 e 90 7,3
SO5 M 41 Ex-SM III No 72,0 28,0 0,0 0,0 0,0 94 95 96 97 5,3
SO6 F 37 NS I No 81,0 15,6 3,4 0,0 0,0 97 98 106 93 3,4
SO7 M 47 NS IV No 84,8 13,8 1,2 e 0,2 63 63 69 68 4,4
SO8 M 33 NS II No 80,8 18,7 0,3 0,2 0,0 93 92 92 94 3,4
SO9 F 74 NS IV No 50,0 38,2 5,6 6,2 0,0 65 64 e 80 4,3
S10 M 44 NS III No 83,6 13,4 1,6 1,2 0,2 70 67 81 57 2,3
S11 F 48 NS III No 91,0 8,2 0,2 0,6 0,0 76 74 83 88 8,3
S12 M 51 NS II No 86,8 10,8 2,0 0,4 0,0 90 91 79 80 2,5
S13 F 51 NS II No 63,7 34,5 0,0 1,0 0,8 89 85 97 95 5,7
514 M 34 Ex-SM I No 64,2 34,2 1,2 0,4 0,0 75 74 76 74 0,7
S15 M 38 NS IV No 71,2 28,4 0,4 0,0 0,0 69 68 75 46 2,5
S16 M 39 NS II No 71,8 27,4 0,8 0,0 0,0 e 95 e 83 17,0
S17 M 39 NS I Yes 86,6 12,8 0,6 0,0 0,0 87 83 84 87 6,0
S18 M 72 SM III e 92,7 6,8 0,3 0,2 0,0 96 99 89 102 4,7
S19 M 32 SM I Yes 71,2 26,6 1,8 0,2 0,0 97 94 102 92 14,0
S20 M 63 Ex-SM II No 74,6 23,0 1,8 0,2 0,2 33 28 e 23 1,4
S21 M 49 SM I No 89,0 9,4 1,6 0,0 0,0 90 93 e 100 0,9
S22 F 44 Ex-SM I Yes 90,8 7,6 1,4 0,2 0,0 99 100 120 92 5,2
S23 F 44 Ex-SM III No 85,0 13,0 1,0 0,8 0,2 83 84 99 81 4,2
S24 M 35 Ex-SM I Yes 55,0 43,4 1,4 0,2 0,0 112 113 106 120 7,9
S25 F 44 NS II No 85,2 14,2 0,4 0,2 0,0 114 117 e 111 3,7
S26 F 32 Ex-SM I Yes 94,8 4,0 1,0 0,2 0,0 e e e e 2,7
S27 F 69 SM III No 28,0 69,0 0,6 2,2 0,2 e 83 82 80 9,3
S28 F 39 SM I Yes e e e e e 95 88 88 86 e
S29 F 58 NS III No 86,6 13,0 0,2 0,0 0,2 71 72 72 75 3,1
S30 M 31 SM II Yes 88,2 10,0 1,6 0,0 0,2 103 104 101 78 2,6
S31 F 37 Ex-SM I Yes 70,0 29,3 0,8 0,0 0,0 93 94 91 82 13,0
(continued on next page)
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286 B. Leva¨nen et al.Immunocytochemistry
An aliquot of bronchial brush biopsy-cells (60,000 cells/
slide) were cytocentrifuged onto SuperFrostPlus glass
slides (Menzel-Gla¨ser, Braunschweig, Germany) for differ-
ential counts and immunocytochemistry. A monoclonal
b-catenin antibody was used as primary antibody (1:100, BD
Biosciences, San Jose, CA) and biotin-conjugated horse
anti-mouse serum (1:300, Vector Laboratories, Burlingame,
CA) as secondary. Briefly, slides were fixed in 4% PFA,
washed in PBS before antigen-retrieval by boiling in citrate
buffer for 15 min and permeabilisation by ice-cold MeOH for
10 min. Endogenous peroxidase activity was blocked by
0.3% H2O2. 5% horse serum in PBS was used to block
unspecific binding. Samples were incubated at 4 C over-
night with primary antibody, and after washing incubated
1h with secondary antibody. Antigen-antibody complexes
were visualised using the Vectastain ABC peroxidase kit
(Vector Laboratories) and DAB-tablets (SigmaeAldrich)
according to the manufacturers’ instructions. Slides were
briefly counter-stained with hematoxylin before mounting.
Cultured Cos-7 cells overexpressing b-catenin were used as
positive controls. Slides were viewed for positive staining
by a manual visual determination by a double blind evalu-
ation completed by two independent observers.
Statistical methods
The results from the electrophoretic mobility shift assays
and RT-PCR data were evaluated by ManneWhitney test.
Correlations between different parameters were deter-
mined with Spearman’s rank correlation test. P values
0.05 were considered to be significant.
Results
We performed semi-quantitative RT-PCR on BAL cells for
selected Wnts, and combined this with EMSA and immuno-
cytochemistry to measure Wnt-signal activation in epithe-
lial cells.
Wnt expression in BAL cells
Expression of Wnt3, -4, -5A, -7A, -7B, -10B and -11 has been
described in lung and lung cell lines.16e20 The lung of
patients with sarcoidosis exhibit accumulation of of
T-lymphocytes and macrophages, that are considered to
have a role in the pathogenesis, and both T cells and
macrophages are a known source of Wnts.21,22 Based on
this, we performed semi-quantitative RT-PCR to investigate
the mRNA expression of Wnt3, Wnt5A, Wnt7A, Wnt7B and
Wnt11 in BAL cells. The results showed significant increases
in Wnt5A (p Z 0.03) and decreases in Wnt7A (p Z 0.04)
expression in patients with sarcoidosis compared to healthy
control subjects (Fig. 1). Changes in Wnt7B expression did
not reach significant levels, but a trend towards an
increased expression could be seen (pZ 0.13). The change
in Wnt7B approached significance when we only included
never-smokers in the comparison (p Z 0.06, data not
shown). There were no detectable levels of Wnt3 and
Wnt11 (data not shown). Subgrouping the sarcoidosis
Wnt-signaling in sarcoidosis 287patients according to their chest radiography stage (9),
revealed changes in expression of all three genes Wnt5A,
Wnt7A and Wnt7B with advancing radiographic stage
(Fig. 2), all reaching significance at more severe disease
stages. All three genes exhibited higher levels of signifi-
cance when only non-smokers were included in the statis-
tical analysis (data not shown). Twelve of the sarcoidosis
patients had Lo¨fgren’s syndrome, and showed a signifi-
cantly lower expression of Wnt7B (p Z 0.02, Fig. 3).
As expected, BAL cell populations differed between
patient and control groups, with a higher number of
lymphocytes in sarcoidosis (Table 2). We investigated
possible correlations between the BAL cell composition and
Wnt mRNA levels by Spearman’s rank correlation tests. No
significant correlations to BAL cell compositions could be
seen (data not shown). Neither could any significant
correlations be seen to age, gender, smoking history, nor to
CD4/CD8 ratios. Thus we concluded that the detected
differences are due to the disease stage rather than any of
these secondary reasons.
Activation of b-catenin in resident lung cells
Prompted by our results of altered Wnt mRNA expression in
BAL cells, we continued by investigating intracellular acti-
vation of Wnt-signaling in resident lung cells. Wnt binding
to its receptors activates b-catenin, which translocates to
the nucleus. There it binds to DNA together with the tran-
scription factor TCF/Lef and promotes transcription. Lung
epithelial cells are known to express several Wnt-recep-
tors.18,23 To monitor Wnt-signal activation, we performed
EMSA on nuclear extracts of epithelial cells obtained by
bronchial brush biopsies during bronchoscopy with
a labeled DNA-oligonucleotide harbouring a TCF/Lef-
binding site. We observed a significant increase of activated
TCF/b-catenin complex in sarcoidosis (Fig. 4 A and B),Figure 1 Wnt expression in patients with sarcoidosis
compared to healthy controls. Quantitative real-time RT-PCR to
assay levels of Wnt5A, Wnt7A and Wnt7B mRNA in patients with
sarcoidosis (n Z 37) compared to controls (n Z 8). Relative
mRNA expression levels are expressed as second logarithm [log
(2)]. Bar indicates median. H Z healthy, S Z sarcoidosis.
*p < 0.05.
Figure 2 Correlation of Wnt expression to sarcoidosis chest
radiographic stages. Quantitative real-time RT-PCR to assay
levels of Wnt5A, Wnt7A and Wnt7B mRNA in patients with
sarcoidosis. Relative mRNA expression levels are expressed as
second logarithm [log(2)]. Bar indicates median. H Z healthy,
S Z sarcoidosis, I-IV Z radiographic stages 1e4. *p < 0.05
[Wnt5A p Z 0.012 (healthy vs X-ray stage I), Wnt7A p Z 0.014
(healthy vs stage III) andWnt7B pZ 0.049 (healthy vs stage IV)].
Figure 3 Correlation of Wnt expression to Lo¨fgren’s vs non-
Lo¨fgren’s syndrome. Quantitative real-time RT-PCR to assay
levels of Wnt5A, Wnt7A and Wnt7B mRNA in patients with
sarcoidosis. Relative mRNA expression levels are expressed as
second logarithm [log(2)]. Bar indicates median. L Z Lo¨fgrens
syndrome, Non-L Z Non-Lo¨fgrens. **p < 0.01.
288 B. Leva¨nen et al.indicating increased Wnt-signal activation in pulmonary
epithelial cells of these patients in comparison with healthy
never-smoking controls.
To confirm the EMSA results indicating an increased
b-catenin signal activation, we performed immunocyto-
chemistry for b-catenin on cytospins prepared from bron-
chial epithelial cells (Fig. 5). Unactivated b-catenin binds to
the cytoplasmic domain of transmembrane cadherins at the
cell membrane. In sarcoidosis, staining at the cell
membrane was weaker than in the healthy controls, and
evidence of nuclear accumulation was observed, together
corroborating that b-catenin has been activated and
translocated to the nucleus. These results thus confirm the
increased levels of Wnt-signal activation in the airway
epithelium of patients with sarcoidosis.
Discussion
The Wnt family of signaling molecules have been demon-
strated to have profound effects on multiple cellular
processes. However, not much is known about their role in
sarcoidosis. We hypothesised that Wnt ligands secreted
from infiltrating inflammatory cells in the pulmonary tissue
could be involved in the disease processes of sarcoidosis.
We thus measured mRNA levels of selected Wnts in BAL
cells, and also found evidence for activation of down-
stream signaling in resident lung cells, together indicating
increased Wnt-activation in sarcoidosis.
The so called canonical pathway is the most well-char-
acterised of the intracellular pathways activated by Wnts.
In this pathway, binding of Wnt ligands to the Frizzled (Fz)
receptors allows the translocation of b-catenin to the
nucleus where it activates the TCF/Lef family of tran-
scription factors.24 Genes stimulated by the WnteTCF/Lef
pathway include inflammatory genes such as Cyclo-
oxygenase-2 (Cox-2)25 and Matrix metalloproteinases
(MMPs),20,26 as well as proliferative genes such as Vascularendothelial growth factor receptor (VEGFR),27 c-myc,28
c-jun,29 Fos-related antigen 1 (fra-1)29 and cyclin D1,30,31
several of which have been demonstrated to be up-regu-
lated in BAL from individuals with sarcoidosis. Thus, the
observed activated Wnt-signaling could play a role in the
inflammatory processes in sarcoidosis.
The inflammation in sarcoidosis and the associated
pulmonary accumulation of T cells and macrophages, and
formation of granulomas, can in the chronic form lead to
fibrosis. Fibrosis usually develops in the later stages of the
inflammation. A possible hypothesis for this is that the
activated infiltrating inflammatory cells produce and
secrete mediators that start a process of epithelial-
mesenchymal signaling that once initiated becomes self-
sustaining. Epithelial-mesenchymal signaling has been
implicated in the pathogenesis of human idiopathic
pulmonary fibrosis (IPF), and aberrant activation of the
Wnteb-catenin signaling pathway was found in fibrotic foci
of patients with IPF.6,32 Similar to our findings in sarcoid-
osis, they showed an increased expression of Wnt7B in IPF.
Recently, by selectively blocking the b-catenin/CBP inter-
action, without interfering with the p300 interaction,
Henderson et al. suggested an important balance between
the two distinct transcriptional pathways in the develop-
ment of fibrosis.33 Emblom-Callahan et al. demonstrated,
by microarray analysis of IPF patients, an alteration of 11
genes within the wnt pathway, with a downregulation of of
dishevelled dsh homolog 1 (DVL1) and an upregulation of
secreted frizzled-related protein 2 (SFRP2) to mention
a couple known to play a role in the development of
fibrosis.34 Thus, the more pronounced changes in Wnt
expression with more advanced radiographic stage, and less
pronounced changes in Lo¨fgren’s syndrome, hint at a role
for Wnts in the fibrosis associated with chronic sarcoidosis.
The BAL cells investigated were not separated into
subpopulations prior to the RT-PCR experiments. This might
affect the results, due to differing compositions of cells
present in the various study groups. Thus, BAL cell differ-
entials were determined for each patient, allowing us to
take this into account in the post-experimental analysis of
the results. Sarcoidosis patients tend to have raised
amounts of T-lymphocytes compared to healthy control
subjects. However, no correlations were observed neither
when comparing levels of Wnt5A, Wnt7A and Wnt7B mRNA
to the amount of lymphocytes and macrophages, nor to
other factors including gender, age, or CD4/CD8 ratio. This
indicates that the observed differences in Wnt expression is
not merely due to differences in BAL cell composition.
Our EMSA and immunocytochemistry results indicate
that the intracellular b-catenin signaling is increased in
epithelial cells from patients with sarcoidosis. Even though
the lung epithelium is not considered to play a central role
in sarcoidosis pathology, these results, using the epithelium
as a reporter, support increased Wnt-signaling in the
sarcoid lung, and indicate that Wnts secreted from infil-
trating inflammatory cells can activate the canonical
pathway of resident lung cells. Moreover, there has been
evidence of b-catenin signaling involvement in the induc-
tion of epithelial-mesenchymal transition (EMT), which is
an important process during fibrotic tissue repair.35 Even
though we observed a decreased expression of Wnt7A in
contrast to the increased levels of Wnt5A and Wnt7B, the
Figure 4 Electrophoretic mobility shift assay for b-catenin activation in patients with sarcoidosis. (A) Electrophoretic mobility
shift assays were performed on nuclear extracts from epithelial cells obtained by fiberoptic bronchoscopy. An oligonucleotide
harbouring a TCF/Lef consensus binding site was end-labeled with [g32-P] ATP, and used as a probe. The arrow-head indicate the
specific TCF/b-catenin complex and the arrow indicate the TCF shift. The TCF/b-catenin complex is the active form and the larger,
stronger complex therefore indicate increased Wnt-signaling in sarcoidosis. As an internal positive control nuclear extract prepared
from U937 cells was used. Representative gel of several experiments (nZ 8). (B) Graphic representation of the Signal-Noise (SeN)
of all the gels included in the study. SeN was calculated for each image separately in order to account for differences in the manual
film processing and associated intensity differences (see also Supplemental Fig. 1). Bar indicates median. H Z healthy,
S Z sarcoidosis. p Z 0.07.
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Figure 5 Nuclear accumulation of b-catenin in patients with sarcoidosis. 1) Immunocytochemistry confirmed the increased levels
of active, i.e. nuclear, b-catenin in epithelial cells from patients with sarcoidosis (nZ 4). Representative image of several slides. 2)
b-catenin normally binds to the cytoplasmic domain of transmembrane cadherins and is involved in cellecell adhesion. This can be
seen on the left on the slides from the healthy controls (n Z 5). In patients with sarcoidosis there is less staining at the cell
membranes and nuclear accumulation of b-catenin is observed (indicated by arrow), which indicates that the b-catenin has
translocated to the nucleus to form the active complex with the transcription factor TCF/Lef. The inserts are representative
images of control staining; negative control (Ctrl) with primary antibody omitted, positive control (þCtrl) cultured Cos-7 cells
overexpressing b-catenin.
290 B. Leva¨nen et al.EMSA and immunocytochemisty showed that down-stream
signaling was increased. This provides evidence that acti-
vation of Wnteb-catenin signaling is dominating, and the
biological significance of the differences in Wnt5 and 7B,
and Wnt7A, remains to be determined. Also, it cannot be
ruled out that other source of Wnts than the BAL cells
investigated here contribute to the activated b-catenin
signaling. In sarcoidosis, T cells and macrophages accumu-
late in the lung. T cells are a known source for Wnts,21 and
it has also been shown that macrophages can produce these
factors in the mouse.22 Our findings thus provide support for
the hypothesis that Wnts secreted by inflammatory cells in
lungs of patients with sarcoidosis activate b-catenin to play
a role in the pathogenesis of sarcoidosis.
Conclusion
In summary, we have found evidence of altered expression of
Wnt5A, Wnt7A and Wnt7B mRNA in BAL-fluid cells, as well as
increased activation of the canonical b-catenin signaling
pathway in resident lung cells of patients with sarcoidosis. As
Wnts and b-catenin are implicated in the processes of
inflammation, migration and fibrosis, these correlative
results between expression of signaling molecule, and acti-
vation of the down-stream pathway, suggest a role for this
signaling pathway in the inflammatory processes of sarcoid-
osis. A possible role in the fibrosis that can develop in the
chronic formof the diseasewarrants further investigations of
these signaling molecules in sarcoidosis.
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